Medtronic
Chronic Disease Medical Device and Therapy Developer
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
5Month21On [date], according to a report by The Wall Street Journal on Wednesday, citing sources familiar with the matter, Medtronic plans to spin off its diabetes business into an independent company.
The new company will be led by the head of Medtronic's diabetes division.Que DallaraLeader,It is estimated to have approximately8000employees, with its headquarters located in Northridge, California. According to reports, the spin-off plan will be carried out in18Completed within the month.
In2024In the fiscal year, Medtronic's diabetes business revenue reached24.88Billion USD, year-on-year growth10.0%, showing certain growth potential. However, the market competition is extremely fierce, Dexcom (DexCom), Abbott (Abbott) and other competitors continue to launch innovative products, posing a threat to Medtronic's market share.Particularly in the U.S. market, the commercialization of Medtronic's diabetes-related products has nearly come to a standstill.Performance mainly relies on the international market.
Trace back to2021Year12In the month, Medtronic receivedFDAThe warning letter pointed out itsMiniMed 600The series of insulin pumps had product safety issues, and the company did not appropriately classify patient risks or initiate a recall. This incident significantly impacted Medtronic's diabetes business, causing it to...2022Diabetes Business Revenue Declines in Fiscal Year3%, and this business has since been a key focus area for the company's operational rectification.
This spin-off is regarded as an important strategic move by Medtronic to optimize its business structure and focus on core areas. Whether the independent diabetes company can reshape its competitive advantages in the market after the split is worth continued attention.